DIA DIRECT: Developing Vaccines for COVID-19
Richard O. Day, DIAFellow, MD
- Professor of Clinical Pharmacology; University of New South Wales, Medicine
- St. Vincent's Hospital, Australia
Professor Richard Day, AM (MBBS, FRACP, MD), is internationally recognized for his research, leadership, and advocacy in support of quality use of medicines. He has been deeply involved in Australia’s National Medicines Policy, culminating in his Chairmanship of the Pharmaceutical Health and Rational Use of Medicines Committee for the Federal Government (1999-2008), and is an active contributor to national resources such as the Australian Medicines Handbook and Therapeutic Guidelines. Professor Day has published over 500 peer-reviewed papers and been cited more than 21,000 times. He was the first non-US President of DIA, and his many awards include Member of the Order of Australia AM (2000) and the AMA Distinguished Service Award (2009).
Keith D Chirgwin, MD
- Deputy Director, Regulatory Affairs, Global Health
- Bill & Melinda Gates Foundation, United States
Dr. Keith Chirgwin joined the Gates Foundation in 2013 as Deputy Director, Regulatory Affairs. He leads regulatory program strategies for the Foundation, working with development partners to ensure the timely and successful development and registration of products . An infectious disease physician with over 25 years of experience across academia and industry, Keith has overseen the regulatory strategy for the successful development and global licensure of several new vaccines and drugs.
- Vice President & Chief Scientific Officer, Viral Vaccines, Vaccine Research Dev
- Pfizer, United States
Julie Louise Gerberding
- Executive Vice President and Chief Patient Officer
- Merck & Co., Inc., United States
Dr. Julie Louise Gerberding, M.D., M.P.H., currently serves as Executive Vice President, Communications, Global Policy, and Population Health & Chief Patient Officer at Merck. She previously served as the Director of the Centers for Disease Control and Prevention (CDC) and the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) under the Bush administration. She hold an MD from Case Western Reserve University, did her residency at USCF, and earned MPH from University of California, Berkley.
- Chief Strategy Officer
- Clover Biopharmaceuticals, China